Ortin Global Limited (BOM:539287)
15.14
-0.14 (-0.92%)
At close: Aug 17, 2026
Ortin Global Revenue
Ortin Global had revenue of 160.00K INR in the quarter ending June 30, 2026, a decrease of -59.80%. This brings the company's revenue in the last twelve months to 356.00K, down -79.47% year-over-year. In the fiscal year ending March 31, 2026, Ortin Global had annual revenue of 1.01M, down -70.66%.
Revenue (ttm)
356.00K
Revenue Growth
-79.47%
P/S Ratio
345.81
Revenue / Employee
118.67K
Employees
3
Market Cap
123.11M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.01M | -2.42M | -70.66% |
| Mar 31, 2025 | 3.43M | -18.84M | -84.61% |
| Mar 31, 2024 | 22.26M | -38.08M | -63.11% |
| Mar 31, 2023 | 60.34M | -21.97M | -26.69% |
| Mar 31, 2022 | 82.31M | 633.62K | 0.78% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 215.51M |
| Unjha Formulations | 152.79M |
| Zenith Healthcare | 107.48M |
| Hamps Bio | 84.75M |
| Norris Medicines | 75.77M |
| Desh Rakshak Aushdhalaya | 66.33M |